If this doesn't give it a kick nothing will. Problem is that no...

If this doesn't give it a kick nothing will.

Problem is that no one in the US of A connects relenza to BOTA.

This is is where previous management failed. This management should go on the front foot in regards to these CDC comments and say that BOTA is pleased to be able to offer the American people, in association with GSK, a drug that has a major health benefit in response to this mutation. Etcetera.